Document is current
Any future updates will be listed below
-
Authors
Virgilio, T.
Chahine, K.
Bansal, H.
Pizzichetti, C.
Renner, L. L.
Capucetti, A.
Bilato, G.
Latino, I.
Morone, D.
Pulfer, A.
Ventura, P.
Mele, F.
Puca, E.
Mangani, D.
Junqueira, C.
Sallusto, F.
Neri, D.
De Luca, R.
Gonzalez, S. F.
-
Funding
Funding for this research was provided by:
Innosuisse – Swiss Innovation Agency (54225.1 IP-LS)
- License Information
-
More Information
Article History
Received: 20 October 2025
Accepted: 19 February 2026
First Online: 3 March 2026
Declarations
:
: Not applicable.
: Dario Neri is a co-founder and shareholder of Philogen (www.philogen.com), a Swiss-Italian biotech company that operates in the field of ligand-based pharmacodelivery. Emanuele Puca, and Roberto De Luca are employees of Philochem AG, a daughter company of Philogen acting as the discovery unit of the group. The company did not affect the authenticity and objectivity of this work.
